Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr78.25 SEK
Change Today -1.50 / -1.88%
Volume 150.2K
As of 11:30 AM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

medivir ab-b shs (MVIRB) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/12/14 - kr140.93
52 Week Low
03/30/15 - kr75.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDIVIR AB-B SHS (MVIRB)

Related News

No related news articles were found.

medivir ab-b shs (MVIRB) Related Businessweek News

No Related Businessweek News Found

medivir ab-b shs (MVIRB) Details

Medivir AB, a research-based specialty pharmaceutical company, develops and markets pharmaceuticals for the treatment of infectious diseases in the Nordic region. It focuses on the research and development of antiviral pharmaceuticals primarily in the hepatitis C area; and other areas, such as bone-related disorders and neuropathic pain. The company also supplies prescription pharmaceuticals, including 16 prescription pharmaceuticals in different therapeutic areas, including Mollipect, Teovent, and Theo-Dur in respiratory organs; Probecid for gout; Nitroglycerin BioPhausia, Digoxin BioPhausia, and Suscard for cardiovascular system; simeprevir for liver disease; Laxabon and Egazil for gastrointestinal system; Xerclear for cold sores; Lithionit and Adasuve for psychiatry; Paraflex for the musculoskeletal system; Citodon and Morfin Special for pain; and Solvezink for zinc deficiency. Medivir AB is headquartered in Stockholm, Sweden.

medivir ab-b shs (MVIRB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medivir ab-b shs (MVIRB) Key Developments

Medivir AB Announces New Clinical Data for the Once-Daily HCV Protease Inhibitor

Medivir AB announced that new clinical data for the once-daily HCV protease inhibitor simeprevir have been presented at the 24th Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Istanbul, Turkey. Six oral and poster presentations on three clinical studies spanning over several development programs including simeprevir in different treatment combinations, durations and populations were held. Major findings in the studies presented: Interferon free combinations In a phase II study up to 95% cure rates were achieved in HCV genotype (GT)1 infected patients treated with a 3-DAA combination of simeprevir, TMC647055/ritonavir and JNJ-56914845. In the phase III TIGER study in treatment-naive patients with chronic HCV GT1 infection conducted in China and Korea 89-91% were cured with simeprevir in combination with pegylated interferon (P) and ribavirin (R) for 12 weeks followed by PR for a further 12 or 36 weeks. The potential to shorten the total simeprevir plus PR treatment to 12 weeks in treatment-naïve hepatitis C patients is being investigated in an on-going phase III study. In the GT1 study arm 76% of the patients were eligible to shorten treatment and of those 66% achieved SVR12 (were cured). In the GT4 study arm 48% of the patients were eligible for shortened treatment and of those with evaluable outcome at the time of analysis 94% had achieved SVR4.

Medivir AB - Analyst/Investor Day

To present the company's operations and give an update about pharmaceuticals and R&D

Medivir AB Announces Board Appointments

Medivir AB announced that Christine Lind has been employed as the Executive Vice President, Strategic Business Development. She will have operational responsibility for the newly created Strategic Business Development function. Christine's most recent position was as Vice President, Business Development at LifeCell Corporation in New York, and she also has twelve years of investment banking experience at Merrill Lynch & Co. and Gerard Klauer Mattison & Co. Christine studied Finance and Information Systems at New York University and also has a Master of Business Administration from Columbia Business School. Ola Burmark has been employed as the Chief Financial Officer. His areas of responsibility include not only operational responsibility for the Finance & Administration function, but also responsibility for Investor Relations. Ola's previous positions include that of CFO at OneMed AB and Aditro Holding AB.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVIRB:SS kr78.25 SEK -1.50

MVIRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVIRB.
View Industry Companies

Industry Analysis


Industry Average

Valuation MVIRB Industry Range
Price/Earnings 2.0x
Price/Sales 1.3x
Price/Book 1.1x
Price/Cash Flow 1.7x
TEV/Sales 0.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVIR AB-B SHS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at